Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Sevelamer (compound)

Name: sevelamer
PubChem Compound ID: 11593706
Molecular formula: C7H14ClNO4
Molecular weight: 211.643 g/mol
Name: sevelamer
Name (isomeric): DB00658
Drug Type: small molecule
Brand: Renagel
Category: Phosphate Binders
CAS number: 152751-57-0
Indication: For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
Patients with end-stage renal disease (ESRD) retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum calcium resulting in ectopic calcification. When the product of serum calcium and phosphorus concentrations (Ca x P) exceeds 55 mg2/dL2, there is an increased risk that ectopic calcifica...
show more »
Mechanism of Action: Sevelamer prevents hyperphosphatemia by binding to dietary phosphate in the gut, preventing its absorption and thus decreasing serum parathyroid hormone levels.
Absorption: Not absorbed following oral administration, however no absorption studies have been performed in patients with renal disease.
Toxicity: Sevelamer has been given to normal healthy volunteers in doses of up to 14 grams per day for eight days with no adverse effects. Sevelamer has been given in average doses up to 13 grams per day to hemodialysis patients. There are no reported overdosages of sevelamer in patients. Since sevelamer is not absorbed, the risk of systemic toxicity is low.
Affected organisms: Humans and other mammals
Drug interaction:
TrovafloxacinSevelamer may decrease the absorption of orally administered Trovafloxacin. The Sevelamer formulation contains iron that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Sevelamer dose to minimize the interaction.
CiprofloxacinSevelamer decreases ciprofloxacin bioavailability
CyclosporineSevelamer decreases the effect of cyclosporine